comparemela.com

Latest Breaking News On - Emicizumab - Page 1 : comparemela.com

Advancements in Hemophilia A Therapies

Steven W. Pipe, MD, explores the latest developments in hemophilia A treatments and prophylactic therapies, including extended half-life agents and a groundbreaking bispecific antibody.

Hemophilia aUnited statesClinical impactBleeding disorderEconomic costsDisease managementHealthcare implicationsHemophilia patientsFinancial burdensBleeding disorder impactHemophilia careComprehensive insightsPatient challengesEconomic considerationsHealthcare costsManaging hemophilia

Emicizumab Demonstrates Efficacy in Treatment of Hemophilia

Patients with hemophilia A experienced prognostic and quality of life benefits from emicizumab (Hemlibra; Genentech) prophylaxis treatment.

Manira borhanyEmicizumab hemlibraHemophilia welfare society karachiHemophilia joint health scoreWorld federation of hemophiliaApplied thrombosisBlood cell conceptWorld federationFunctional independence scoreRare bloodBlood disorder

Long-Term Hemophilia A Therapies and Their Impact

Lisa Schrade, PharmD, and Robert Sidonio Jr, MD, MSc, discuss real-world evidence for hemophilia A therapies, highlighting their safety, efficacy, and impact on bleeding events, nurse visits, and hospital visits.

Jonathan ogurchakLisa schradeRobert sidonio jrHemophiliaa therapiesReal world evidenceLong term dataAnnualized bleed rateFactor productsTreatment optionsHemophilia careIntravenous infusionSubcutaneous injectionProphylaxis therapyClinical trials

Hemophilia A Treatment Pathways: Acute versus Prophylaxis

Atta Chowdhry, RPh, discusses treatment approaches for acute episodes and prophylaxis in patients with hemophilia A.

Atta chowdhryJonathan ogurchakHemophilia aTreatment pathwaysAcute treatmentFactor replacementJoint damage preventionCombination therapyInfusion practices

Shared Decision-Making in Hemophilia A Therapies

Robert Sidonio Jr, MD, MSc, discusses patient-centered therapy choices, highlighting the diverse options and considerations for hemophilia A treatment.

United statesJonathan ogurchakRobert sidonio jrHemophiliaa therapiesShared decision makingPatient outcomesTherapy selectionFactor replacementTreatment optionsPatient valuesIntravenous products

vimarsana © 2020. All Rights Reserved.